September 09, 2009 09:04 ET

Geisinger Medical Center Proactively Enhances Its Medication Safety Program by Selecting the ValiMed™ Medication Safety System

TUCSON, AZ--(Marketwire - September 9, 2009) - CDEX Inc. (OTCBB: CEXI) ( -- Worldwide studies show that high-risk medication compounding errors in pharmacies continue to cause significant harm to patients and economic loss to hospitals. Geisinger Medical Center joins a growing list of world-class hospitals that are proactively addressing this issue by selecting the ValiMed™ Medication Safety System to assure the "Right Drug at the Right Dose" every time. ValiMed is used to validate accurate compounding of high-risk medications and to reduce the diversion of return narcotics in healthcare facilities.

"After reading the University of Michigan Health System study that documented ValiMed's identification of five major medical mistakes over an 18 month period at one hospital, I knew that we needed to bring that technology in-house," said John Jones, Geisinger Vice President, System Therapeutics. "We purchased two ValiMed units to provide additional assurance of accuracy of our compounding practices."

"We are honored that Geisinger Medical Center selected ValiMed as part of its Medication Safety Program and look forward to working with John and his staff in integrating ValiMed into their daily practices," said Greg Firmbach, Senior Vice President of CDEX.

About CDEX

CDEX develops, manufactures and globally distributes products to the healthcare and security markets. The ValiMed™ product line provides life-saving validation of high-risk medications and returned narcotics and is distributed by companies such as Grifols, S.A. The ID2™ product line detects trace amounts of illegal drugs, such as methamphetamine, and is distributed by companies such as Decatur Electronics (part of Bowmer and Kirkland Limited). CDEX expects to advance its patented technologies to serve additional markets. To meet its plans, CDEX must strengthen its financial position as stated periodically in its SEC filings. For more information, contact Malcolm Philips at

Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.

Contact Information